Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.
about
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia BManufacturing of recombinant adeno-associated viral vectors for clinical trialsAdeno-associated virus-mediated cancer gene therapy: current statusChallenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene TherapyGene therapy for hemophiliaDownstream processing and chromatography based analytical methods for production of vaccines, gene therapy vectors, and bacteriophagesProgress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin DeficiencyDevelopment and utility of an internal threshold control (ITC) real-time PCR assay for exogenous DNA detectionBarriers to inhaled gene therapy of obstructive lung diseases: A reviewPassive immunization against HIV/AIDS by antibody gene transfer.Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza.Sustained normalization of neurological disease after intracranial gene therapy in a feline model.Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9.Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthaseGene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.Gene Therapy 2017: Progress and Future Directions.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes.Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression.Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice.The AAV vector toolkit: poised at the clinical crossroadsFactor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of CancerRobust Lentiviral Gene Delivery But Limited Transduction Capacity of Commonly Used Adeno-Associated Viral Serotypes in Xenotransplanted Human Skin.Recombinant AAV Vectors for Enhanced Expression of Authentic IgG.Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndromeAAV-based RNAi silencing of NADPH oxidase gp91(phox) attenuates cold-induced cardiovascular dysfunctionStrategies to circumvent humoral immunity to adeno-associated viral vectors.Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level.Alleviation of lung inflammatory responses by adeno-associated virus 2/9 vector carrying CC10 in OVA-sensitized miceSafety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin.Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of AchromatopsiaTransgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.CpG-depleted adeno-associated virus vectors evade immune detection.Immune responses to AAV vectors: overcoming barriers to successful gene therapy
P2860
Q21245486-A5F50961-53C4-4736-AB71-1950D1983A33Q26750799-AECBBB19-4346-4805-93C1-984621BC5E95Q27026177-349B36D7-2BE0-42B6-8E36-381CFCC2F9CDQ28080450-45656540-6B47-475A-A7D3-1F2B1A70E76CQ28081911-6AC1768E-6F05-4568-88A5-F06C233ECB5EQ28082234-5A73A9D5-6499-4DFC-87C5-8908EB055034Q28085148-3940F2C7-2A75-46BA-92B8-DCBAFF774182Q28730144-2272E30F-DABC-408D-8928-568CE8CF8ED2Q29248141-248C65AA-CD95-45BA-8664-F9709C33675AQ30358434-E915DFA2-E815-4979-ACDB-271B6507164AQ30431225-AF8BC145-404D-46F0-BB75-4D536B76D5A2Q30644848-CBD13FA8-1FE7-4542-A396-98762AF3CD42Q33586940-5685E5EF-2A75-4DEE-A24F-6EB4F2882B50Q33782838-F6526351-2E5E-41A3-9F05-CC9573AE3386Q33881920-B006F448-8928-41BF-9B86-04DD92C744FAQ33891559-C6857F6E-1848-48B2-9572-97A810BBA78AQ33902499-7CB43E23-C9E9-4A2B-8A5E-FB8C5B2CA8EAQ33938435-79BBE8BB-49FE-454F-8805-4E63D2FF5BBFQ34311144-26C181D5-B1B9-4DD0-B97F-0F8BDA36D5F1Q34633598-3180814A-3C3D-4B6B-9C22-6F2C73EA3E93Q34634722-F89C7722-E207-4C2D-9B0E-0EC7E0DC4826Q35063726-44809270-5FD6-4C8B-9FA8-E1B78B26D789Q35418068-E740A0A1-E87C-47ED-BF67-AA544A94AF45Q35821871-9AA27597-21A7-4124-9C13-5EB108685C68Q35876224-F8D47819-7DB9-4864-9612-8DAAC2D48E3BQ35876970-443244E1-10EF-498B-AD7D-C556D9A84B96Q35949356-F26C993D-4550-4556-B2DE-B812999C2C32Q36010698-FB6E4935-35BD-4BDC-B1AD-DA513B52333CQ36058890-4D57F171-68F3-41D1-9BEE-9D6657DF7359Q36084447-C4334634-C77B-4119-9898-35AF0F69FE86Q36228880-8799804E-7E09-4C1C-8665-4BD0A0D244C8Q36398678-2DE85BFF-DC31-486A-896D-B71BCB2FB130Q36512576-B8E7821B-2E16-4480-9CEB-15B52960003CQ36562646-185486D5-DF9B-4B17-90C3-6BDF3FEDBA5FQ36677162-E34E1FA9-4897-4750-89FC-5E43F673C5C5Q36709834-50CF0453-F34E-4D94-BE49-20A386F81225Q36852206-EDCE82CD-3A08-43E4-91C4-44D1CDD4FBFAQ36950042-B5F0FD3A-5AE7-42F1-96EF-E80E03F21EC4Q36966955-44B4BC4B-39A1-4E2E-9F3C-F3A1E17508B8Q36983740-D88FD9D5-8F9D-4CFE-A9B6-CCB28BBBA63A
P2860
Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase 2 clinical trial of a re ...... -antitrypsin: interim results.
@ast
Phase 2 clinical trial of a re ...... -antitrypsin: interim results.
@en
type
label
Phase 2 clinical trial of a re ...... -antitrypsin: interim results.
@ast
Phase 2 clinical trial of a re ...... -antitrypsin: interim results.
@en
prefLabel
Phase 2 clinical trial of a re ...... -antitrypsin: interim results.
@ast
Phase 2 clinical trial of a re ...... -antitrypsin: interim results.
@en
P2093
P2860
P356
P1433
P1476
Phase 2 clinical trial of a re ...... -antitrypsin: interim results.
@en
P2093
Anthony T Yachnis
Brenna Carey
Bruce C Trapnell
Christian Mueller
David R Knop
Farshid Rouhani
Guo-jie Ye
Jeffrey D Chulay
Louis M Messina
Margaret Humphries
P2860
P304
P356
10.1089/HUM.2011.053
P577
2011-08-24T00:00:00Z